Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion Pharmaceuticals Inc has experienced a significant downturn in financial performance, with revenue growth plummeting to -32.98% in Q3 2025 from +30.14% in Q2 2025. Profitability metrics are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback